Log in to save to my catalogue

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection...

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04483589v1

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

About this item

Full title

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Publisher

United States: Elsevier Ltd

Journal title

The Lancet infectious diseases, 2024-05, Vol.24 (5), p.523-534

Language

English

Formats

Publication information

Publisher

United States: Elsevier Ltd

More information

Scope and Contents

Contents

Staphylococcus aureus bloodstream infection is treated with at least 14 days of intravenous antimicrobials. We assessed the efficacy and safety of an early switch to oral therapy in patients at low risk for complications related to S aureus bloodstream infection.
In this international, open-label, randomised, controlled, non-inferiority trial do...

Alternative Titles

Full title

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04483589v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04483589v1

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(23)00756-9

How to access this item